Transplantation re-thought

Transplantation without rejection -
a lifelong solution

We create an immunological invisibility of the donor organ instead of inducing immunological blindness in the organ recipient.

Infographic that shows that Allogenetics soliution applied to donor organ, turns the donor organ invisible and thus becomes a lifelong transplant without immunosuppression
Disadvantage of the current method

Lifelong immunosuppression burdens the recipient with an incompetent immune system, depriving the recipient of a healthy, uncompromised life

Organ Engineering to Prevent Rejection

Genetic Organ Modification

Our vision is a completely new approach to solving the problem of organ rejection:
instead of inducing immunological blindness in the organ recipient, an immunological invisibility of the donor organ will be created – for a life without rejection and immunosuppression, better graft survival, better quality of life and more available organs.

The Difference in the Approach

Our Approach
Current Approach
Organ Rejection
Compentent immune system

The aim is to reduce the immunogenicity of donor organs by selectively and permanently switching off the HLA antigens that are the targets of T cells and antibodies causing rejection.

As a result, the targets for immunologically mediated rejection are missing, so that an organ can no longer be recognized as foreign.

Infographic showing the donor organ without HLA antigens
Incompentent immune system

HLA antigens are the targets of T cells and antibodies, both of which cause rejection. Immunosuppression leads to the inactivation of the immune cells and the attenuation of rejection, but at the expense of a functioning immune system.

Infographic shows the incompetent t cell that is not reacting to the HLA antigens due to immunosuppression
Organ rejection

When neither the immune system is blinded nor the organ is made invisible, the transplant is being rejected by the recognition of HLA antigens.

Infographic showing the donor organ with HLA antigens to which the t cells have reacted. Thus the organ is being rejected.

Understanding the Invisible Tissue

Immune System’s Mechanism
to identify allogenetic cells

The immunogenicity of a transplant is determined by the gene products of the Major Histocompatibility Complex (MHC), which in humans are referred to as Human Leukocyte Antigens (HLA). The mechanism by which the immune system recognizes allogeneic cells as foreign is based on the recognition of these HLA-antigens on the cell surface by cytotoxic T-cells and antibodies.

The HLA antigens are extremely polymorphic, so that thousands of variants exist which trigger organ rejection in case of a mismatched organ transplant.

But even in the case of an extremely rare complete HLA match between donor and recipient, rejection occurs regularly because short peptides from all endogenous proteins are presented in the HLA molecules, which exhibit countless disparities between genetically distinct individuals and are referred to as minor histocompatibility antigens (mHag).

The route to no immunosuppression

The concept of tissue marker deactivation is based on a genetic modification of the organs by viral transduction during ex vivo perfusion in an organ preservation system. The cells are genetically modified in such a way that the MHC genes can no longer be expressed as proteins on the cell surface.

Infographic showing the allogenetics solution with the lentiviral vector which turns the donor organ invisible.

The elimination of these target structures of immunological rejection at the donor-recipient interface leads to immunological invisibility of the modified cells to the recipient's immune system.

An immunological recognition as foreign is thus no longer possible despite a fully functional immune system of the recipient. In previous investigations with cells and tissues, rejection could be completely prevented in this way without the need for immunosuppression.

Pipeline

10%
icon of a liver
Development Stage
Discovery
20%
icon of a heart
Development Stage
Preclinical
30%
icon of a kidney
Development Stage
Preclinical
60%
icon of a lung
Development Stage
Clinical Phase 1

About Us

Allogenetics GmbH offers a completely new solution to the problem of organ rejection after transplantation. The Allogenetics approach is a unique first-in-class therapeutic as it treats the transplant instead of paralyzing the patient's immune system. This innovation offers a new dimension in organ transplantation: Invisible organs instead of lifelong immunosuppression.

Allogenetics: For a life without rejection and immunosuppression, for better graft survival and better quality of life.

Team

Prof. Dr. Rainer Blasczyk, MD

Founder and CEO
Biography

Prof. Dr. Constanca Figueiredo, PhD

Founder and CSO
Biography

Philipp Langrehr, MSc Economics

Founder and CFO
Biography

Investors Relations

Allogenetics GmbH is supported by renowned investors to advance the development of organ transplantation technology.
Please contact us for further information.

Contact Us
Icon of a book
Investor Handout

We provide detailed information about Allogenetics GmbH for evaluation.

download